Gobinda Sarkar

Dr. Gobinda Sarkar


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GSGobinda Sarkar
Gobinda Sarkar
GCGeoffry L. Curran
Geoffry L. Curran
EMEric Mahlum
Eric Mahlum
TDTeresa Decklever
Teresa Decklever
TWThomas M. Wengenack
Thomas M. Wengenack
RJRobert B. Jenkins
Robert B. Jenkins
Therapeutic intervention of numerous brain-associated disorders currently remains unrealized due to serious limitations imposed by the blood-brain-barrier (BBB). The BBB generally allows transport of small molecules, typically <600 daltons with high octanol/water partition coefficients, but denies passage to most larger molecules. However, some receptors present on the BBB allow passage of cognate proteins to the brain. Utilizing such receptor-ligand systems, several investigators have developed methods for delivering proteins to the brain, a critical requirement of which involves covalent linking of the target protein to a carrier entity. Such covalent modifications involve extensive preparative and post-preparative chemistry that poses daunting limitations in the context of delivery to any organ. Here, we report creation of a 36-amino acid peptide transporter, which can transport a protein to the brain after routine intravenous injection of the transporter-protein mixture. No covalent linkage of the protein with the transporter is necessary. A peptide transporter comprising sixteen lysine residues and 20 amino acids corresponding to the LDLR-binding domain of apolipoprotein E (ApoE) was synthesized. Transport of beta-galactosidase, IgG, IgM, and antibodies against amyloid plques to the brain upon iv injection of the protein-transporter mixture was evaluated through staining for enzyme activity or micro single photon emission tomography (micro-SPECT) or immunostaining. Effect of the transporter on the integrity of the BBB was also investigated. The transporter enabled delivery to the mouse brain of functional beta-galactosidase, human IgG and IgM, and two antibodies that labeled brain-associated amyloid beta plaques in a mouse model of Alzheimer's disease. The results suggest the transporter is able to transport most or all proteins to the brain without the need for chemically linking the transporter to a protein. Thus, the approach offers an avenue for rapid clinical evaluation of numerous candidate drugs against neurological diseases including cancer. (299 words).

1 May 2004 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
HHHiroshi Hatano
Hiroshi Hatano
HSHerrick J. Siegel
Herrick J. Siegel
HYHiroshi Yamagiwa
Hiroshi Yamagiwa
JBJames T. Bronk
James T. Bronk
RTRussell T. Turner
Russell T. Turner
GSGobinda Sarkar
Gobinda Sarkar

21 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GSGobinda Sarkar
Gobinda Sarkar
GCGeoffry L. Curran
Geoffry L. Curran
JSJann N. Sarkaria
Jann N. Sarkaria
VLVal J. Lowe
Val J. Lowe
RJRobert B. Jenkins
Robert B. Jenkins
Rapid pre-clinical evaluation of chemotherapeutic agents against brain cancers and other neurological disorders remains largely unattained due to the presence of the blood-brain barrier (BBB), which limits transport of most therapeutic compounds to the brain. A synthetic peptide carrier, K16ApoE, was previously developed that enabled transport of target proteins to the brain by mimicking a ligand-receptor system. The peptide carrier was found to generate transient BBB permeability, which was utilized for non-covalent delivery of cisplatin, methotrexate and other compounds to the brain. Brain delivery of the chemotherapeutics and other agents was achieved either by injecting the carrier peptide and the drugs separately or as a mixture, to the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a ‘small-molecule’ drug. Seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the method, brain uptake with K16ApoE was 0.72–1.1% for cisplatin and 0.58–0.92% for methotrexate (34-50-fold and 54–92 fold greater for cisplatin and methotrexate, respectively, with K16ApoE than without). Visually intense brain-uptake of Evans Blue, Light Green SF and Crocein scarlet was also achieved. Direct intracranial injection of EB show locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection of EB resulted in the distribution of the dye throughout the brain. Experiments with insulin suggest that ligand-receptor signaling intrinsic to the BBB provides a natural means for passive transport of some molecules across the BBB. The results suggest that the carrier peptide can non-covalently transport various chemotherapeutic agents to the brain. Thus, the method offers an avenue for pre-clinical evaluation of various small and large therapeutic molecules against brain tumors and other neurological disorders.

1 September 1998 in BioTechniques
Verified
Journal Article
Open access
KWKristy L. Weber
Kristy L. Weber
MBMark E. Bolander
Mark E. Bolander
GSGobinda Sarkar
Gobinda Sarkar
The determination of unknown DNA sequences around a known locus has important applications in molecular genetics, specifically in genomic walking and genome mapping. Several PCR-based methods have been reported to address this issue, but they often involve multiple, time-consuming steps. We have previously described a technique known as restriction site PCR (RSPCR) that allows sequence acquisition faster than the existing methods. The method involves PCR using four separate universal primers that are representative of given restriction enzyme sites (RS primers), and a specific primer from one end of the known sequence. We have now significantly improved the technique by mixing the four universal primers into one PCR tube with the first specific primer. This is followed by a nested PCR with the mixed RS primers and an internal specific primer, after which the product is sequenced by direct automated sequencing. The technique, called multiplex RS-PCR (mRS-PCR), is reproducible and can be used to obtain unkn...

1 September 2007 in Gene
Verified
Journal Article
Closed access
BFBruno Fuchs
Bruno Fuchs
EMEric Mahlum
Eric Mahlum
CHChandralekha Halder
Chandralekha Halder
AMAvudaippan Maran
Avudaippan Maran
MYMichael Yaszemski
Michael Yaszemski
GSGobinda Sarkar
Gobinda Sarkar

1 October 1997 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ASArunik Sanyal
Arunik Sanyal
SOShawn W. O’driscoll
Shawn W. O’driscoll
MBMark E. Bolander
Mark E. Bolander
GSGobinda Sarkar
Gobinda Sarkar